Los Angeles Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Los Angeles Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,701	Closed	-$18K	–	2410
2025 Q4	$18K	Buy	+4,701	New	+$16.6K	﹤0.01%	1903
2022 Q2	–	Sell	-88,887	Closed	-$246K	–	1329
2022 Q1	$246K	Buy	88,887 +34,630	+64%	+$126K	﹤0.01%	1307
2021 Q4	$289K	Hold	54,257	–	–	﹤0.01%	1251
2021 Q3	$459K	Sell	54,257 -5,120	-9%	-$50.6K	﹤0.01%	1091
2021 Q2	$724K	Buy	+59,377	New	+$1.17M	﹤0.01%	1001

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Los Angeles Capital Management's BDTX Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 4,701 shares — an estimated $18K sold.

Los Angeles Capital Management first reported a position in BDTX in Q2 2021 and held it in 5 quarters. The position peaked at $724K in Q2 2021. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Los Angeles Capital Management reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
Los Angeles Capital Management sold 4,701 Black Diamond Therapeutics shares in Q1 2026, an estimated $18K.
Los Angeles Capital Management first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 5 quarters.
Los Angeles Capital Management's Black Diamond Therapeutics position peaked at $724K in Q2 2021.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.